It is uncertain whether the combination of HER2-targeted agents and mTOR inhibitors might provide benefit in patients with HER2-positive gastric cancer who became resistant: the identification of predictive biomarkers remains crucial for optimizing efficacy. The gene discussed is ERBB2; the disease is gastric cancer.